Wei Wang

Wei Wang

Auto-generated profile, based on publicly available information

Wei Wang

Department of Cellular Biology, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
DPDuo Peng
Duo Peng
RBRodrigo de Paula Baptista
Rodrigo de Paula Baptista
YLYiran Li
Yiran Li
JKJessica C. Kissinger
Jessica C. Kissinger
RTRick L. Tarleton
Rick L. Tarleton
The protozoan Trypanosoma cruzi almost invariably establishes life-long infections in humans and other mammals, despite the development of potent host immune responses that constrain parasite numbers. The consistent, decades-long persistence of T. cruzi in human hosts arises at least in part from the remarkable level of genetic diversity in multiple families of genes encoding the primary target antigens of anti-parasite immune responses. However, the highly repetitive nature of the genome–largely a result of these same extensive families of genes–have prevented a full understanding of the extent of gene diversity and its maintenance in T. cruzi. In this study, we have combined long-read sequencing and proximity ligation mapping to generate very high-quality assemblies of two T. cruzi strains representing the apparent ancestral lineages of the species. These assemblies reveal not only the full repertoire of the members of large gene families in the two strains, demonstrating extreme diversity within and between isolates, but also provide evidence of the processes that generate and maintain that diversity, including extensive gene amplification, dispersion of copies throughout the genome and diversification via recombination and in situ mutations. Gene amplification events also yield significant copy number variations in a substantial number of genes presumably not required for or involved in immune evasion, thus forming a second level of strain-dependent variation in this species. The extreme genome flexibility evident in T. cruzi also appears to create unique challenges with respect to preserving core genome functions and gene expression that sets this species apart from related kinetoplastids.

28 October 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JBJuan M. Bustamante
Juan M. Bustamante
FSFernando Sanchez-Valdez
Fernando Sanchez-Valdez
APAngel M. Padilla
Angel M. Padilla
BWBrooke White
Brooke White
WWWei Wang
Wei Wang
RTRick L. Tarleton
Rick L. Tarleton
A modified regimen of benznidazole prevents Trypanosoma cruzi dormancy-dependent treatment failure in several mouse models of Chagas disease.

27 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
MKMarkus Kainulainen
Markus Kainulainen
NJNannan Jiang
Nannan Jiang
HDHan Di
Han Di
GBGaston Bonenfant
Gaston Bonenfant
BZBin Zhou
Bin Zhou
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.

9 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NJNannan Jiang
Nannan Jiang
LWLi Wang
Li Wang
MHMasato Hatta
Masato Hatta
CFChenchen Feng
Chenchen Feng
MCMichael Currier
Michael Currier
BZBin Zhou
Bin Zhou
The early Omicron lineage variants evolved and gave rise to diverging lineages that fueled the COVID-19 pandemic in 2022. Bivalent mRNA vaccines, designed to broaden protection against circulating and future variants, were authorized by the U.S. Food and Drug Administration (FDA) in August 2022 and recommended by the U.S. Centers for Disease Control and Prevention (CDC) in September 2022. The impact of bivalent vaccination on eliciting neutralizing antibodies against homologous BA.4/BA.5 viruses as well as emerging heterologous viruses needs to be analyzed. In this study, we analyze the neutralizing activity of sera collected after a third dose of vaccination (2-6 weeks post monovalent booster) or a fourth dose of vaccination (2-7 weeks post bivalent booster) against 10 predominant/recent Omicron lineage viruses including BA.1, BA.2, BA.5, BA.2.75, BA.2.75.2, BN.1, BQ.1, BQ.1.1, XBB, and XBB.1. The bivalent booster vaccination enhanced neutralizing antibody titers against all Omicron lineage viruses tested, including a 10-fold increase in neutralization of BQ.1 and BQ.1.1 viruses that predominated in the U.S. during the last two months of 2022. Overall, the data indicate the bivalent vaccine booster strengthens protection against Omicron lineage variants that evolved from BA.5 and BA.2 progenitors.

24 March 2025 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SJSophie Jones
Sophie Jones
RSRichard Stanton
Richard Stanton
MDMarisa D’ANgeli
Marisa D’ANgeli
ABAudrey Brezak
Audrey Brezak
JSJenna Sinkevitch
Jenna Sinkevitch
MWMaroya Spalding Walters
Maroya Spalding Walters
In the United States, New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacterales (CRE) are frequently associated with healthcare encounters. From September 2021 to September 2022, 21 patients with NDM-CRE identified from urine and without healthcare exposure were reported to the Centers for Disease Control and Prevention. Isolates were genetically similar to healthcare-associated strains.

11 March 2026 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CVCarolina Silva Dias Vieira
Carolina Silva Dias Vieira
WWWei Wang
Wei Wang
FSFernando Sanchez-Valdez
Fernando Sanchez-Valdez
JLJihyun Lim
Jihyun Lim
BWBrooke E. White
Brooke E. White
NNNatalia P. A. Nogueira
Natalia P. A. Nogueira
Trypanosoma cruzi , the causative agent of Chagas disease, possesses glycosomes—unique organelles that house key metabolic enzymes, several of which are promising therapeutic targets. Among them, phosphoenolpyruvate carboxykinase (PEPCK) plays a central role in succinic fermentation, the main pathway for NAD + regeneration within the organelle. Using CRISPR/Cas9 editing, the PEPCK gene was disrupted in T. cruzi , producing single‐allele knockout epimastigotes (TcPEPCK‐sKO) with reduced PEPCK expression and enzyme activity. In a high glucose environment, PEPCK disruption impaired glucose consumption and mitochondrial respiration, particularly oxidative phosphorylation, reducing dependence on mitochondrial ATP production when glucose was supplied. To compensate, pyruvate phosphate dikinase was upregulated, increasing alanine production, possibly to maintain redox balance in glycosomes. Despite this metabolic adaptation, the growth of TcPEPCK‐sKO epimastigotes was partially reduced compared with non‐deleted parasites. In contrast, under low glucose conditions, PEPCK activity was not critical for mitochondrial bioenergetics, ATP production, or proliferation. Although TcPEPCK‐sKO epimastigotes exhibited a minor reduction in growth in high glucose medium, their differentiation (metacyclogenesis) and invasion were severely compromised. However, once inside the host cell, TcPEPCK‐sKO amastigotes increased their replication, leading to enhanced trypomastigote production. The same was observed in in vivo infection, where TcPEPCK‐sKO infection in IFNγ‐deficient mice caused uncontrolled parasitemia and severe pathology, highlighting the critical role of PEPCK in host‐pathogen interactions. However, an intact immune system effectively contained TcPEPCK‐sKO infection. Taken together, our findings demonstrate that glycosomal PEPCK is crucial for coupling glycolysis to mitochondrial bioenergetics, enabling the parasite differentiation within the insect vector and controlling the infection of mammalian host cells.